Monitoring of Neurological Adverse Effects Induced by Immunosuppressants.
|
Accession number;99A0450011
|
| Title;Monitoring of Neurological Adverse Effects Induced by Immunosuppressants. |
| Author;
SHUTO HIDEKI
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
HIRAKAWA MASAAKI
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
MAKINO KAZUTAKA
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
SUEYASU MASANORI
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
KATAOKA YASUFUMI
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
OISHI RYOZO
(Kyushu Univ., Univ. Hosp. Attach. to the Fac. of Med.)
|
Journal Title;Japanese Journal of Hospital Pharmacy
|
Journal Code:Y0888A
|
ISSN:0389-9098
|
|
VOL.25;NO.2;PAGE.103-111(1999)
|
| Figure&Table&Reference;FIG.7, TBL.4, REF.14 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Cyclosporine- or tacrolimus-induced neurotoxicity was retrospectively evaluated in five patients. Symptoms ranging from mild(tremor, insomnia, visual disturbance) to severe events(convulsion, leukoencephalopathy) were observed. The predisposing risk factors in these patients included hypomagnesemia, liver dysfunction and transient high blood concentrations of the immunosuppressants. Besed on our findings as well as those from other reports, the initial signs and symptoms of immunosuppressant-induced neurotoxicity were as follows; tremor, headache, anorexia, nausea, vomiting, lethargy, insomnia, anxiety, amnesia, visual disturbance. However, not all of these events correlated with the blood concentrations of the immunosuppressants. The blood cyclosporine concentrations decreased by concomitant use of phenytoin. The blood tacrolimus concentrations varied markedly during the two-week-period after liver transplantation. To prevent patients from developing serious events under immunosuppressant therapy, pharmacists should thus recognize the predisposing risk factors in patients, and carefully monitor the initial signs related to neurotoxicity and the blood concentrations of the patients receiving immunosuppressants. (author abst.) |
|
|
|
Related Articles;
|
|
